Return to Non–Small-Cell Lung Cancer Specialty Channel

Non–Small-Cell Lung Cancer Interactive Features

KEYNOTE‑189 study results revealed the addition of pembrolizumab to _______ improves both survival and progression free survival in metastatic NSCLC, irrespective of the tumor PD‑L1 expression.
Which of the following treatments recently received FDA approval for ALK+ Non-Small Cell Lung Cancer?
True or false: Platinum-based chemotherapy demonstrated a longer overall survival than atezolizumab in NSCLC patients with high PD-L1 expression.
True or false: Moderate neutropenia levels predict improved OS in NSCLC after gem-carbo therapy.
True or false: Tepotinib therapy initiated a complete response in approximately 60% of patients with advanced NSCLC and MET exon 14 skipping mutation, in a recent trial.
True or False: Population-based death rates from NSCLC in the United States dramatically declined between 2013 and 2016.
True or False: A deep learning survival neural network model displays potential benefit in prognostic evaluation and treatment recommendations, with respect to lung cancer–specific survival.
Which combination yielded manageable safety and encouraging antitumor activity in patients with mesothelin-expressing solid tumors?
Stay in the know.
OncNet Newsletter